The US Food and Drug Administration (FDA) has approved AbbVie’s Epkinly (epcoritamab-bysp) to treat adult patients with ...

Survival rates also varied significantly by stage. In the combined analysis for men and women without metastasis, the ...

The five-year survival rate for male and female patients in Japan who were diagnosed with pancreatic cancer between 2012 and 2015 came to 10.7 pct and 10.2 pct, respectively, the lowest among all ...

AbbVie (NYSE: ABBV) today announced that EPKINLY® (epcoritamab-bysp), a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab and lenalidomide (EPKINLY + R2) ...

Genmab ( ($GMAB) ) just unveiled an update. On November 18, 2025, Genmab A/S announced that the U.S. FDA approved EPKINLY® (epcoritamab-bysp) in ...

Company AnnouncementEPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific-based therapy approved by the FDA for ...

The U.S. Food and Drug Administration (FDA) has approved Epkinly (epcoritamab-bysp) plus Revlimid (lenalidomide) and Rituxan ...

The autologous CAR-T cell therapy MB-105 has received regenerative medicine advanced therapy (RMAT) designation from the FDA ...

Researchers sought to determine whether glofitamab would induce responses in real-world cases of relapsed or refractory DLBCL.

A phase 1 trial reveals that combining radiotherapy with immunotherapy enhances response rates in B-cell lymphomas while maintaining manageable safety profiles.

A cancer diagnosis for a beloved family dog is heart-wrenching. Not all lymphomas are the same, however, and prognoses differ for each.